As were into a new year I believe that we're approaching the point where we'll see explosive growth in IMGN based on anticipation that IMGN853 is headed for approval. That probably won't occur until 2020, and no data should be revealed in the Phase 3 Trial, but data from the various other trials where the drug is being used in various combinations appears very positive, and should only get better as the best dosage to use is determined.
Beyond that, their IGN's have been impressive to date. The first, which has the same target as what was abandoned by SGEN has gone through 11 dose escalations and MTD still hasn't been seen, efficacy has been seen. The second is just beginning it's first clinical trial.
Last year the stock was up roughly 300%, but I expected more. This year should be at least that good, but I believe $20's or higher is possible. The all time high for IMGN was in the $40's many years ago, I believe that will be exceeded in 2019 or 2020, and it could come sooner on a really lucrative partnership for IMGN853. IMGN has made it clear that they want to keep North America, or at least the U.S. but are looking for a ROW partner. This drug certainly has blockbuster potential and ought to bring in hundreds of millions or more in a partnership IMHO.
Gary |
